RT Journal Article
SR Electronic
T1 Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.28.22282808
DO 10.1101/2022.11.28.22282808
A1 Patel, Vishal
A1 Yarwood, Marcus J.
A1 Levick, Bethany
A1 Gibbons, Daniel C.
A1 Drysdale, Myriam
A1 Kerr, William
A1 Watkins, Jonathan D.
A1 Young, Sophie
A1 Pierce, Benjamin F.
A1 Lloyd, Emily J.
A1 Birch, Helen J.
A1 Kamalati, Tahereh
A1 Brett, Stephen J.
YR 2022
UL http://medrxiv.org/content/early/2022/11/29/2022.11.28.22282808.abstract
AB Introduction There is limited real-world evidence surrounding the effectiveness of early, mild-to-moderate COVID-19 treatments following the emergence and dominance of Omicron SARS-CoV-2 subvariants. Here, characteristics and acute clinical outcomes are described for patients with COVID-19 treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or patients at highest risk per NHS criteria but who were untreated.Methods Retrospective cohort study of non-hospitalised patients who received early treatment for, or were diagnosed with, COVID-19 between 1 December 2021 and 31 May 2022, using data from the Discover dataset in north-west London. Patients were included if aged ≥12 years and treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or were untreated but expected to be eligible for early treatment per NHS highest-risk criteria at time of diagnosis. Outcomes were reported for 28 days from COVID-19 diagnosis (index). Subgroup analyses were conducted in patients with advanced renal disease, those aged 18–64 and ≥65 years and by period of Omicron BA.1, BA.2 and BA.5 (post-hoc exploratory analysis) predominance.Results A total of 696 patients prescribed sotrovimab, 337 prescribed nirmatrelvir/ritonavir, 470 prescribed molnupiravir and 4,044 eligible high-risk untreated patients were included. A high proportion of patients on sotrovimab had advanced renal disease (29.3%), ≥3 high-risk comorbidities (47.6%) and were aged ≥65 years (36.9%). In total, 5/696 (0.7%) patients on sotrovimab, <5/337 (0.3–1.2%) patients on nirmatrelvir/ritonavir, 10/470 (2.1%) patients on molnupiravir and 114/4,044 (2.8%) untreated patients were hospitalised with COVID-19 as the primary diagnosis. Similar results were observed across all subgroups and during Omicron subvariant periods.Conclusion Patients who received sotrovimab appeared to show evidence of multiple comorbidities that may increase risk of severe COVID-19. Low hospitalisation rates were observed for all treated cohorts across subgroups and periods of predominant variants of concern. These descriptive results require confirmation with comparative effectiveness analyses adjusting for differences in underlying patient characteristics.Why carry out this study?There is limited real-world evidence surrounding early, mild-to-moderate COVID-19 treatments, particularly during Omicron subvariant dominance periods, and the UK National Institute for Health and Care Excellence has recommended more is gathered.We described patient characteristics and clinical outcomes among patients treated with sotrovimab, nirmatrelvir/ritonavir, molnupiravir or who met the highest-risk eligibility criteria but were untreated.What was learned from the study?Sotrovimab was often utilised amongst more elderly and at-risk patients, such as those with advanced renal disease, than patients treated with nirmatrelvir/ritonavir or molnupiravir.We found that hospitalisation rates were low across all treated cohorts.For patients treated with sotrovimab, clinical outcomes appeared consistent when observed across the age subgroups and Omicron subvariant periods, as well as among patients with advanced renal disease.Competing Interest StatementVP, DCG, MD, WK, EJL and HJB are employees of, and/or shareholders in, GSK. MJY, JDW, SY, BFP and TK are employees of Imperial College Health Partners, which received funding from GSK to conduct the study. BL is an employee of OPEN Health, which received funding from GSK to conduct the study. A consultancy fee was paid to SJB’s institutional account.Funding StatementThis study was funded by GSK (study number 214907).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Discover Data Access Group (DRAG) which has derogated powers to approve studies under its overarching approval as a Health Research Database. This study complies with all applicable laws regarding subject privacy. Data were aggregated and counts less than five were suppressed in line with IG suppression rules. No direct subject contact or primary collection of individual human subject data occurred. Study results were in tabular form and aggregate analyses that omit subject identification, therefore informed consent, ethics committee or IRB approval were not required. Any publications and reports do not include subject identifiers.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Discover-NOW data that support the findings of this study are available from Imperial College Health Partners via approval from the Discover Data Access Group (DRAG) under certain restrictions.